Cargando…
Translating tissue engineering technology platforms into cancer research
Technology platforms originally developed for tissue engineering applications produce valuable models that mimic three-dimensional (3D) tissue organization and function to enhance the understanding of cell/tissue function under normal and pathological situations. These models show that when replicat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828855/ https://www.ncbi.nlm.nih.gov/pubmed/19627398 http://dx.doi.org/10.1111/j.1582-4934.2009.00853.x |
_version_ | 1782291295371264000 |
---|---|
author | Hutmacher, Dietmar W Horch, Raymund E Loessner, Daniela Rizzi, Simone Sieh, Shirly Reichert, Johannes C Clements, Judith A Beier, Justus P Arkudas, Andreas Bleiziffer, Oliver Kneser, Ulrich |
author_facet | Hutmacher, Dietmar W Horch, Raymund E Loessner, Daniela Rizzi, Simone Sieh, Shirly Reichert, Johannes C Clements, Judith A Beier, Justus P Arkudas, Andreas Bleiziffer, Oliver Kneser, Ulrich |
author_sort | Hutmacher, Dietmar W |
collection | PubMed |
description | Technology platforms originally developed for tissue engineering applications produce valuable models that mimic three-dimensional (3D) tissue organization and function to enhance the understanding of cell/tissue function under normal and pathological situations. These models show that when replicating physiological and pathological conditions as closely as possible investigators are allowed to probe the basic mechanisms of morphogenesis, differentiation and cancer. Significant efforts investigating angiogenetic processes and factors in tumorigenesis are currently undertaken to establish ways of targeting angiogenesis in tumours. Anti-angiogenic agents have been accepted for clinical application as attractive targeted therapeutics for the treatment of cancer. Combining the areas of tumour angiogenesis, combination therapies and drug delivery systems is therefore closely related to the understanding of the basic principles that are applied in tissue engineering models. Studies with 3D model systems have repeatedly identified complex interacting roles of matrix stiffness and composition, integrins, growth factor receptors and signalling in development and cancer. These insights suggest that plasticity, regulation and suppression of these processes can provide strategies and therapeutic targets for future cancer therapies. The historical perspective of the fields of tissue engineering and controlled release of therapeutics, including inhibitors of angiogenesis in tumours is becoming clearly evident as a major future advance in merging these fields. New delivery systems are expected to greatly enhance the ability to deliver drugs locally and in therapeutic concentrations to relevant sites in living organisms. Investigating the phenomena of angiogenesis and anti-angiogenesis in 3D in vivo models such as the Arterio-Venous (AV) loop mode in a separated and isolated chamber within a living organism adds another significant horizon to this perspective and opens new modalities for translational research in this field. |
format | Online Article Text |
id | pubmed-3828855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-38288552015-04-27 Translating tissue engineering technology platforms into cancer research Hutmacher, Dietmar W Horch, Raymund E Loessner, Daniela Rizzi, Simone Sieh, Shirly Reichert, Johannes C Clements, Judith A Beier, Justus P Arkudas, Andreas Bleiziffer, Oliver Kneser, Ulrich J Cell Mol Med Reviews Technology platforms originally developed for tissue engineering applications produce valuable models that mimic three-dimensional (3D) tissue organization and function to enhance the understanding of cell/tissue function under normal and pathological situations. These models show that when replicating physiological and pathological conditions as closely as possible investigators are allowed to probe the basic mechanisms of morphogenesis, differentiation and cancer. Significant efforts investigating angiogenetic processes and factors in tumorigenesis are currently undertaken to establish ways of targeting angiogenesis in tumours. Anti-angiogenic agents have been accepted for clinical application as attractive targeted therapeutics for the treatment of cancer. Combining the areas of tumour angiogenesis, combination therapies and drug delivery systems is therefore closely related to the understanding of the basic principles that are applied in tissue engineering models. Studies with 3D model systems have repeatedly identified complex interacting roles of matrix stiffness and composition, integrins, growth factor receptors and signalling in development and cancer. These insights suggest that plasticity, regulation and suppression of these processes can provide strategies and therapeutic targets for future cancer therapies. The historical perspective of the fields of tissue engineering and controlled release of therapeutics, including inhibitors of angiogenesis in tumours is becoming clearly evident as a major future advance in merging these fields. New delivery systems are expected to greatly enhance the ability to deliver drugs locally and in therapeutic concentrations to relevant sites in living organisms. Investigating the phenomena of angiogenesis and anti-angiogenesis in 3D in vivo models such as the Arterio-Venous (AV) loop mode in a separated and isolated chamber within a living organism adds another significant horizon to this perspective and opens new modalities for translational research in this field. Blackwell Publishing Ltd 2009-08 2009-07-20 /pmc/articles/PMC3828855/ /pubmed/19627398 http://dx.doi.org/10.1111/j.1582-4934.2009.00853.x Text en © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd |
spellingShingle | Reviews Hutmacher, Dietmar W Horch, Raymund E Loessner, Daniela Rizzi, Simone Sieh, Shirly Reichert, Johannes C Clements, Judith A Beier, Justus P Arkudas, Andreas Bleiziffer, Oliver Kneser, Ulrich Translating tissue engineering technology platforms into cancer research |
title | Translating tissue engineering technology platforms into cancer research |
title_full | Translating tissue engineering technology platforms into cancer research |
title_fullStr | Translating tissue engineering technology platforms into cancer research |
title_full_unstemmed | Translating tissue engineering technology platforms into cancer research |
title_short | Translating tissue engineering technology platforms into cancer research |
title_sort | translating tissue engineering technology platforms into cancer research |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828855/ https://www.ncbi.nlm.nih.gov/pubmed/19627398 http://dx.doi.org/10.1111/j.1582-4934.2009.00853.x |
work_keys_str_mv | AT hutmacherdietmarw translatingtissueengineeringtechnologyplatformsintocancerresearch AT horchraymunde translatingtissueengineeringtechnologyplatformsintocancerresearch AT loessnerdaniela translatingtissueengineeringtechnologyplatformsintocancerresearch AT rizzisimone translatingtissueengineeringtechnologyplatformsintocancerresearch AT siehshirly translatingtissueengineeringtechnologyplatformsintocancerresearch AT reichertjohannesc translatingtissueengineeringtechnologyplatformsintocancerresearch AT clementsjuditha translatingtissueengineeringtechnologyplatformsintocancerresearch AT beierjustusp translatingtissueengineeringtechnologyplatformsintocancerresearch AT arkudasandreas translatingtissueengineeringtechnologyplatformsintocancerresearch AT bleizifferoliver translatingtissueengineeringtechnologyplatformsintocancerresearch AT kneserulrich translatingtissueengineeringtechnologyplatformsintocancerresearch |